Professor Kellum is seen as one of the top ICU nephrologists worldwide. He has carried out a significant part of the preclinical work for CytoSorb. He has no doubts about the medical efficiency of this therapy and is very much involved in the efforts to generate the needed data and evidence to make it standard of care.
“I think that this particular technology is unique. One of the unique properties is that it is more biocompatible than typical adsorbents…”
Dr. Grootendorst is one of the leading intensive care physicians in the Netherlands. He is doing active research for decades in the field of cytokine removal and high-volume hemofiltration. He has introcuced CytoSorb at his hospital and is excited about the therapeutic effects he has seen. Dr. Grootendorst is currently preparing the publication on his clinical results with CytoSorb.
“The effectiveness of CytoSorb is based on the removal of mediators of sepsis that cause renal failure, liver failure, ARDS, etc. So it is not a symptomatic therapy, like we used to do. Now, we try to treat the cause of the ARDS and of the renal failure…”
Professor Molnar is among the leading intensive care physicians in Hungary. Furthermore he is President of the SepsEast Forum, an organization dedicated to the fight against sepsis and its burden. For him CytoSorb represents potentially a great tool to treat and avoid the devastating complications in septic shock. Professor Molnar is currently conducting a pilot trial with CytoSorb in septic shock patients.
“My view on the future of CytoSorb therapy is that it will, I think, go towards a so called individualized treatment. […] Some patients will need it for 12 hours, and others may need it for 72 hours…”
“Critically ill patients with severe SIRS who do no longer respond to standard treatment are the target group that benefits most from CytoSorb. The CytoSorb adsorber should be used as early as possible in order to stabilize the patient and thus bring about a turn for the better. Adsorption therapy with CytoSorb is very user-friendly. The quick reduction of catecholamines without rebound effect was a sustainable treatment effect. Patients could be weaned from the respirator earlier than expected.”
“In major cardio-vascular surgery it is of course an advantage to have a tool available that eliminates these mediators. Especially in patients with high infection and inflammation parameters, CytoSorb is the means of choice. We use the adsorber if long surgery durations are anticipated and if patients undergo repeated surgery or need to be on CPB for a long time. I expect that in the next years, CytoSorb will become a standard therapy in re-do cardiac surgery. In addition, I think it might be possible that CytoSorb is used in patients with cardiogenic shock or under resuscitation who are treated with ECLS.”
“Through the use of CytoSorb, we can possibly prevent kidney failure or incipient acute kidney injury and avoid hemodialysis by specifically removing high levels of myoglobin, so that ultimately it can no longer harm the renal tubules. I think that preventing renal failure is more sensible than treating it later on and that CytoSorb therapy is safe and user-friendly.”
Have you also already asked yourself these questions on the CytoSorb therapy?
These internationally renowned experts give answers to these and some more questions on the basis of their experience around the CytoSorb therapy: